By Ryan Holeywell | April 13, 2022 New York’s newly-signed budget contains a key reform that could be nothing short of lifesaving for some cancer patients living in the state. The new budget, signed by Gov. Kathy Hochul Saturday, will make National Cancer Institute-designated cancer centers “in-network” for over 5…

By Lee Greenberger, PhD, Chief Scientific Officer at LLS | April 5, 2022 The U.S. Food and Drug Administration (FDA) last week approved axicabtagene ciloleucel (axi-cel, Yescarta®) for patients with large B-cell lymphoma (LBCL) who either did not respond to first-line standard chemotherapy or relapsed within 12 months. Until now, CAR T-therapies like axi-cel have been saved for blood cancer patients who have…

By Lee Greenberger, PhD, Chief Scientific Officer at LLS | March 1, 2022 Ciltacabtagene Autoleucel (cilta-cel) is the second CAR-T approved to treat multiple myeloma Just one year after the first CAR T-cell treatment was approved for multiple myeloma, the second is about to hit the market. The FDA approved…

By Lee Greenberger, Ph.D., LLS Chief Scientific Officer The American Society of Hematology (ASH) annual meeting is the premier scientific forum on blood cancers. More than 5,000 potentially game-changing research abstracts were presented at this year’s meeting. Every year, I come away with a strengthened sense of hope about new…

The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR T-cell treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Roughly half of all ALL cases occur in adults, and unlike pediatric ALL, adults have historically had…

The Leukemia & Lymphoma Society (LLS) and Burlington Stores are marking two decades of an incredible partnership this year. With Burlington’s help, LLS has been able to provide free information, education, and 1:1 support for hundreds of thousands of blood cancer patients. And we’re still going strong. Continuing the momentum…

The Leukemia & Lymphoma Society (LLS) was founded more than 70 years ago by a family, for families. Our mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma, and improve the quality of life of patients and their families. Today, we are the leading source of free information, education…

Meetings with lawmakers, testimonies at state legislatures, and events with passionate volunteers are all staples of advocacy. Historically, those are some of the ways we accomplish that work. But COVID-19 prompted us to rethink the way our staff and volunteers share their message with lawmakers. LLS and its Office of…

By Lee Greenberger, Ph.D., LLS Chief Scientific Officer The U.S. Food and Drug Administration (FDA) yesterday approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™) as a component of a chemotherapy regimen used to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in patients who are allergic to other commonly used asparaginase…